Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Carcinoma, Non-Small-Cell Lung 361Lung Neoplasms 195Breast Neoplasms 163Ovarian Neoplasms 129Triple Negative Breast Neoplasms 79Squamous Cell Carcinoma of Head and Neck 73Small Cell Lung Carcinoma 67Fallopian Tube Neoplasms 56Head and Neck Neoplasms 46Carcinoma, Ovarian Epithelial 44Neoplasms 40Neoplasm Metastasis 39Esophageal Neoplasms 36Adenocarcinoma of Lung 36Esophageal Squamous Cell Carcinoma 29Prostatic Neoplasms 27Endometrial Neoplasms 27Uterine Cervical Neoplasms 23Brain Neoplasms 23Central Nervous System Neoplasms 22Urinary Bladder Neoplasms 21Carcinoma, Squamous Cell 21Recurrence 20Neuroblastoma 20Lymphoma, Large B-Cell, Diffuse 20Melanoma 19Lymphoma 19Carcinoma 19Adenocarcinoma, Bronchiolo-Alveolar 18Testicular Neoplasms 15

Interventions

trametinib 1dabrafenib 1Vincristine 1Carboplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Ganglioneuroma × Carboplatin × Clear all
NCT02684058 2023-12-13

Study of Efficacy and Safety of Dabrafenib in Combination With Trametinib in Pediatric Patients With BRAF V600 Mutation Positive LGG or Relapsed or Refractory HGG Tumors

Novartis

Phase 2 Completed
151 enrolled 45 charts 1 FDA
CNS

Astrocytoma, Ganglioneuroma, Glioblastoma, Glioma, Oligodendroglioma, Ganglioglioma, Neurocytoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡